McGill researchers identified potentially fatal overactivated cellular pathways caused by COVID, and three existing drugs that can reduce mortality.
An important discovery linking a specific RNA structure and invasive breast cancer cells could enable new therapies that stop the spread of cancer.
RNA research can help us predict the likelihood of a rare inherited tumour causing cancer in children and adolescents.
A McGill lab is developing RNA therapies against the HIV and SARS-CoV-2 viruses, as well as conducting work on the Zika virus.
Amélie Quesnel-Vallée is helping non-profit, governmental and private partners make data-driven decisions around public health that respect the realities of underserved communities.
RNA biologist Jerry Pelletier’s research on fundamental biology is facilitating the development of RNA therapeutics as novel anti-cancer drugs.
As Canada’s leading expert on mRNA, Nahum Sonenberg’s research has improved our understanding of diseases like cancer, diabetes, autism and fragile X syndrome.
Amine Kamen’s work in vaccine development and biomanufacturing helps ensure that safe, effective vaccines can reach the patients who need them.
The development of new RNA therapies requires leading experts in a range of fields like machine learning, fundamental biology, medicine and more, to work together.
The McGill Centre for RNA Sciences (MCRS) is developing new drugs based on RNA targeting and gene editing, all while training the next generation of RNA leaders.
Throughout the pandemic, McGill’s researchers have demystified the science behind the mRNA vaccines.
Alleviating the impact of the COVID-19 pandemic on children, youth and families a priority for McGill researchers.